However, the results of these studies indicated that there were considerable reductions in the incidence of any or severe bleeding events in adult ITP patients receiving TPO-RAs compared with control patients (RR: 0.84, 95% CI: 0.74–0.96; RR: 0.49, 95% CI: 0.24–0.97; respectively Supplementary Fig. S5, Table 3). Here, TPO is linked to autoimmune thrombocytopenic purpura.